Zealand Pharma and Generate Biomedicines partner on AI protein drugs
Zealand Pharma has signed a collaboration and licence agreement with Generate Biomedicines to develop multispecific protein therapeutics for obesity and other metabolic diseases, paying the Cambridge, Massachusetts-based AI drug-design company $30 million up front and committing to up to $35 million in early preclinical milestones. Generate is also eligible for total milestone payments of nearly $1.2 billion, plus tiered royalties on worldwide net sales, across two initial programmes, with an option for Zealand to add a third.
Under the structure of the deal, Generate will lead research through to lead-candidate selection using its generative AI platform, which pairs computational protein design with large-scale experimental validation. Zealand Pharma will then assume responsibility for clinical development, regulatory submissions, and global commercialisation. The division of labour reflects a model that is becoming increasingly common in AI-enabled drug discovery: the technology partner de-risks early design; the pharma partner absorbs the clinical and commercial risk.
The strategic logic for Zealand
The deal extends Zealand Pharma's modality repertoire beyond the peptide chemistry that has defined the Copenhagen-based company since its founding in 1998. Zealand already has two marketed products and three late-stage candidates, all drawing on more than 25 years of peptide research and development. Adding protein-based multispecific candidates opens polypharmacology approaches that are difficult to prosecute with peptides alone, a relevant consideration in obesity and cardiometabolic disease where combination mechanisms are increasingly favoured by clinical opinion.
Utpal Singh, chief scientific officer at Zealand Pharma, said the collaboration "expands our toolbox to include proteins, complementing our existing small-molecule and peptide capabilities and opening new approaches for polypharmacology for innovative therapeutics." Generate chief executive Mike Nally framed the partnership around "continued unmet medical need for patients with cardiometabolic disease."
Market context and competitive read-across
The partnership lands at a moment of intense activity in obesity drug development. The commercial success of GLP-1 receptor agonists has mobilised most large pharmaceutical companies and a growing cohort of biotechs to pursue next-generation mechanisms, including multispecific approaches that combine GLP-1 with complementary targets such as GIP, glucagon, or amylin receptors. Zealand itself has a GLP-1/GLP-2 dual agonist and other metabolic candidates in its pipeline, giving it direct clinical insight to inform target selection for the new programmes.
On the AI drug-design side, Generate competes in a field that includes Insilico Medicine, Recursion Pharmaceuticals, and Isomorphic Labs, among others. What distinguishes Generate's stated approach is the tight coupling of generative model outputs with high-throughput wet-lab validation, a loop that the company argues narrows the gap between computational prediction and biological reality. Whether that translates into a differentiated clinical candidate in obesity, a notoriously competitive indication, remains the open question for investors.
The financial terms are substantial by early-stage collaboration standards. A $30 million up-front payment is a meaningful signal of Zealand's commitment, and the $1.2 billion milestone ceiling, while contingent on a long chain of clinical and regulatory events, reflects the commercial scale of the obesity market. Analysts will focus on the pace of lead-candidate selection and any disclosure of the specific targets being pursued, neither of which was detailed in the announcement. Both companies are NASDAQ-listed, and the deal is expected to appear in forthcoming quarterly filings.